190 related articles for article (PubMed ID: 1502008)
1. Influence of co-medication on the metabolism of valproate.
Pisani F
Pharm Weekbl Sci; 1992 Jun; 14(3A):108-13. PubMed ID: 1502008
[TBL] [Abstract][Full Text] [Related]
2. Pharmacologic interactions between valproate and other drugs.
Bourgeois BF
Am J Med; 1988 Jan; 84(1A):29-33. PubMed ID: 3146222
[TBL] [Abstract][Full Text] [Related]
3. Differentiation between valproate-induced anticonvulsant effect, teratogenicity and hepatotoxicity. Aspects of species variation, pharmacokinetics, metabolism and implications of structural specificity for the development of alternative antiepileptic agents such as delta 2-valproate.
Nau H; Siemes H
Pharm Weekbl Sci; 1992 Jun; 14(3A):101-7. PubMed ID: 1502007
[TBL] [Abstract][Full Text] [Related]
4. Clinically significant pharmacokinetic drug interactions with carbamazepine. An update.
Spina E; Pisani F; Perucca E
Clin Pharmacokinet; 1996 Sep; 31(3):198-214. PubMed ID: 8877250
[TBL] [Abstract][Full Text] [Related]
5. Formation of active metabolites of anticonvulsant drugs. A review of their pharmacokinetic and therapeutic significance.
Eadie MJ
Clin Pharmacokinet; 1991 Jul; 21(1):27-41. PubMed ID: 1914340
[TBL] [Abstract][Full Text] [Related]
6. Drug interactions with valproic acid.
Levy RH; Koch KM
Drugs; 1982 Dec; 24(6):543-56. PubMed ID: 6818015
[TBL] [Abstract][Full Text] [Related]
7. Effects of three N-(carboxyanilinomethyl) derivatives of p-isopropoxyphenylsuccinimide on the anticonvulsant action of carbamazepine, phenobarbital, phenytoin and valproate in the mouse maximal electroshock-induced seizure model.
Luszczki JJ; Cioczek JD; Kocharov SL; Andres-Mach M; Kominek M; Zolkowska D
Eur J Pharmacol; 2010 Dec; 648(1-3):74-9. PubMed ID: 20826140
[TBL] [Abstract][Full Text] [Related]
8. Effects of polytherapy with phenytoin, carbamazepine, and stiripentol on formation of 4-ene-valproate, a hepatotoxic metabolite of valproic acid.
Levy RH; Rettenmeier AW; Anderson GD; Wilensky AJ; Friel PN; Baillie TA; Acheampong A; Tor J; Guyot M; Loiseau P
Clin Pharmacol Ther; 1990 Sep; 48(3):225-35. PubMed ID: 2119269
[TBL] [Abstract][Full Text] [Related]
9. Effect of xanthotoxin (8-methoxypsoralen) on the anticonvulsant activity of classical antiepileptic drugs against maximal electroshock-induced seizures in mice.
Zagaja M; Pyrka D; Skalicka-Wozniak K; Glowniak K; Florek-Luszczki M; Glensk M; Luszczki JJ
Fitoterapia; 2015 Sep; 105():1-6. PubMed ID: 26026802
[TBL] [Abstract][Full Text] [Related]
10. Can we develop improved derivatives of valproic acid?
Bialer M; Haj-Yehia A; Badir K; Hadad S
Pharm World Sci; 1994 Feb; 16(1):2-6. PubMed ID: 8156045
[TBL] [Abstract][Full Text] [Related]
11. Valproate-associated hepatotoxicity and its biochemical mechanisms.
Eadie MJ; Hooper WD; Dickinson RG
Med Toxicol Adverse Drug Exp; 1988; 3(2):85-106. PubMed ID: 3131628
[TBL] [Abstract][Full Text] [Related]
12. Isobolographic analysis of interactions between remacemide and conventional antiepileptic drugs in the mouse model of maximal electroshock.
Borowicz KK; Malek R; Luszczki JJ; Ratnaraj N; Patsalos PN; Czuczwar SJ
Epilepsy Behav; 2007 Aug; 11(1):6-12. PubMed ID: 17602881
[TBL] [Abstract][Full Text] [Related]
13. 2-phosphonomethyl-pentanedioic acid (glutamate carboxypeptidase II inhibitor) increases threshold for electroconvulsions and enhances the antiseizure action of valproate against maximal electroshock-induced seizures in mice.
Luszczki JJ; Mohamed M; Czuczwar SJ
Eur J Pharmacol; 2006 Feb; 531(1-3):66-73. PubMed ID: 16403497
[TBL] [Abstract][Full Text] [Related]
14. Steady-state dispositions of valproate and diflunisal alone and coadministered to healthy volunteers.
Addison RS; Parker-Scott SL; Eadie MJ; Hooper WD; Dickinson RG
Eur J Clin Pharmacol; 2000 Dec; 56(9-10):715-21. PubMed ID: 11214782
[TBL] [Abstract][Full Text] [Related]
15. Aspects of the metabolism of valproic acid.
Granneman GR; Wang SI; Machinist JM; Kesterson JW
Xenobiotica; 1984 May; 14(5):375-87. PubMed ID: 6433565
[TBL] [Abstract][Full Text] [Related]
16. The interactions of atorvastatin and fluvastatin with carbamazepine, phenytoin and valproate in the mouse maximal electroshock seizure model.
Stepien KM; Tomaszewski M; Luszczki JJ; Czuczwar SJ
Eur J Pharmacol; 2012 Jan; 674(1):20-6. PubMed ID: 22056838
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic and pharmacodynamic interactions of valproate, phenytoin, phenobarbitone and carbamazepine with curcumin in experimental models of epilepsy in rats.
Reeta KH; Mehla J; Pahuja M; Gupta YK
Pharmacol Biochem Behav; 2011 Sep; 99(3):399-407. PubMed ID: 21641922
[TBL] [Abstract][Full Text] [Related]
18. Effect of naproxen co-administration on valproate disposition.
Addison RS; Parker-Scott SL; Hooper WD; Eadie MJ; Dickinson RG
Biopharm Drug Dispos; 2000 Sep; 21(6):235-42. PubMed ID: 11304722
[TBL] [Abstract][Full Text] [Related]
19. Metabolism of valproate to hepatotoxic intermediates.
Baillie TA
Pharm Weekbl Sci; 1992 Jun; 14(3A):122-5. PubMed ID: 1502011
[TBL] [Abstract][Full Text] [Related]
20. [Valproate-associated hepatotoxicity--pathogenesis, clinical aspects, therapy and prevention].
Siemes H; Nau H
Klin Padiatr; 1991; 203(6):411-9. PubMed ID: 1758143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
